Journal article
Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires
- Abstract:
-
Modern pharmacovigilance began in the 1960s, since when the subject has grown markedly, interest having particularly increased since 2010. One index of its success is the increasing speed with which serious adverse drug reactions are discovered after marketing of a medicinal product. However, the speed with which products have subsequently been withdrawn as a result of the discovery of serious adverse reactions has not consistently changed. This highlights problems that regulators and manufac...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 137.6KB)
-
- Publisher copy:
- 10.1016/j.therap.2017.02.005
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Thérapie Journal website
- Volume:
- 72
- Issue:
- 5
- Pages:
- 555-561
- Publication date:
- 2017-03-30
- Acceptance date:
- 2017-03-05
- DOI:
- EISSN:
-
1958-5578
- ISSN:
-
0040-5957
- Pmid:
-
28461037
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:846614
- UUID:
-
uuid:a7075927-48dc-48f0-b32a-66c1f3182ae0
- Local pid:
- pubs:846614
- Source identifiers:
-
846614
- Deposit date:
- 2018-08-17
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2017
- Notes:
- © 2017 Published by Elsevier Masson SAS on behalf of Soci´et´e franc¸aise de pharmacologie et de th´erapeutique. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.therap.2017.02.005
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record